Abstract
Communications about the safety of medicines are complex and generally poorly performed. Discussions may not be initiated by healthcare professionals and the lack of a ‘common language’ to express risk can cause confusion. In the event of a serious adverse drug reaction, prior failures in communication can cause difficulties, and patients may fail to receive adequate information about the nature of their experience. How to communicate openly with patients in order to minimize distrust and maximize future benefits from medicines requires exploration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE 2009 Feb 11; 4(2): e4439
Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–9
Barry CA, Bradley CP, Britten N, et al. Patients’ unvoiced agendas in general practice consultations: qualitative study. BMJ 2000; 320(7244): 1246–50
Tarn DM, Heritage J, Paterniti DA, et al. Physician communication when prescribing new medications. Arch Intern Med 2006; 166(17): 1855–62
Richard C, Lussier MT. Nature and frequency of exchanges on medications during primary care encounters. Patient Educ Couns 2006; 64(1–3): 207–16
Feng B, Bell RA, Jerant AF, et al. What do doctors say when prescribing medications? An examination of medical recommendations from a communication perspective. Health Commun 2011 Apr 14; 26(3): 286–96
Dickinson D, Raynor DKT. What information do patients need about medicines? Ask the patients — they may want to know more than you think. BMJ 2003; 327: 861
Brown C, Battista DR, Bruehlman R, et al. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 2005; 43(12): 1203–7
Lamb GC, Green SS, Heron J. Can physicians warn patients of potential side effects without fear of causing those side effects? Arch Intern Med 1994; 154(23): 2753–6
Regulation (EU) No. 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards Pharmaco vigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products [online]. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf [Accessed 2012 Aug 21]
Committee on Safety of Medicines. Report of the working party on adverse reactions: part I. London: Department of Health and Society Security, 1983
Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study. BMJ 1998; 317: 119–20
Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK “Yellow Card Scheme”: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess 2011 May; 15(20): 1–234, iii-iv
Berry DC, Raynor DK, Knapp P, et al. Patients’ understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales. Drug Saf 2003; 26(1): 1–11
Paling J. Helping patients understand risks: 7 simple strategies for successful communication. 1st ed. Gainesville (FL): Risk Communication Institute, 2006
Patient decision aids [online]. Available from URL: http://www.npc.nhs.uk/patient_decision_aids/ [Accessed 2012 Jan 3]
Ziegler DK, Mosier MC, Buenaver M, et al. How much information about adverse effects of medication do patients want from physicians? Arch Intern Med 2001; 161(5): 706–13
Fraenkel L, Peters E. Patients reaction to the disclosure of rare dreaded adverse effects. Patient Educ Couns 2011; 84: e1–4
Tarn DM, Paterniti DA, Williams BR, et al. Which providers should communicate which critical information about a new medication? Patient, pharmacist, and physician perspectives. J Am Geriatr Soc 2009 Mar; 57(3): 462–9
Butt TF, Cox AR, Lewis H, et al. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Saf 2011; 34(4): 319–28
Lorimer S, Cox A, Langford N. A patient’s perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther 2012; 37: 148–52
Butt TF, Cox AR, Oyebode JR, et al. Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Saf. In press
Duclos CW, Eichler M, Taylor L, et al. Patient perspectives of patient-provider communication after adverse events. Int J Qual Health Care 2005; 17(6): 479–86
Gallagher TH, Waterman AD, Ebers AG, et al. Patients’ and physicians’ attitudes regarding the disclosure of medical errors. JAMA 2003; 289: 1001–7
Lamb R. Open disclosure: the only approach to medical error. Qual Saf Health Care 2004 Feb 1; 13(1): 3–5
Kachalia A, Kaufman SR, Boothman R, et al. Liability claims and costs before and after implementation of a medical error disclosure program. Ann Intern Med 2010; 153(4): 213–21
Acknowledgements
No funding was provided for this article and the authors have no conflicts of interest.
This article is part of a theme issue co-edited by Priya Bahri, European Medicines Agency, UK, and Mira Harrison-Woolrych, New Zealand Pharmacovigilance Centre, New Zealand. No external funding was used to support the publication of this theme issue.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cox, A.R., Butt, T.F. Adverse Drug Reactions. Drug Saf 35, 977–981 (2012). https://doi.org/10.1007/BF03261985
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03261985